Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Colchicine in Acute Myocardial Infarction.

Name: Kaimen Rigor review — Colchicine in Acute Myocardial Infarction.
Item: Colchicine in Acute Myocardial Infarction.
Rating: 39
Author: Alpha1

Jolly SS, d'Entremont MA, Lee SF, Mian R, Tyrwhitt J, Kedev S, Montalescot G, Cornel JH, Stanković G, Moreno R, Storey RF, Henry TD, Mehta SR, Bossard M, Kala P, Layland J, Zafirovska B, Devereaux PJ, Eikelboom J, Cairns JA, Shah B, Sheth T, Sharma SK, Tarhuni W, Conen D, Tawadros S, Lavi S, Yusuf S, CLEAR Investigators

Paper source

Read full text

Embed this Rigor badge

Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Colchicine in Acute Myocardial Infarction.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Colchicine in Acute Myocardial Infarction.

Read full text

DOI

10.1056/NEJMoa2405922

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/9db5c8f6-a3d3-473b-abb3-e930f58dc949" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/9db5c8f6-a3d3-473b-abb3-e930f58dc949/badge" alt="Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Colchicine in Acute Myocardial Infarction.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

5cdb643392898a59f05e73f869491949e38e1491a294a98b1b354283f8e5e78a

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Colchicine in Acute Myocardial Infarction.

Paper source

Colchicine in Acute Myocardial Infarction.

Read full text

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 6 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues2 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
2.7% does not match the reported count 137/3528
“Coronary artery bypass grafting (%) 137 (2.7)”
Table 1Find in source
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
2.8% does not match the reported count 139/3534
“Coronary artery bypass grafting (%) 139 (2.8)”
Table 1Find in source

Findings by category

201ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit7 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized clinical trial with rigorous design, clear ethics approvals, and appropriate statistical methods. The main weaknesses are the absence of a data availability statement, lack of explicit statistical software identification, and minor copyedit issues including a potential denominator inconsistency.

This is an interventional clinical trial; all dimensions were applicable except those specific to animal or cell-line research. The two reviewers agreed on all dimensions; no divergence to reconcile. The statistics verification covered only a subset of tests (5 recomputed, 3 consistent, 2 inconsistent but no decision errors), so the statistical analysis is not fully verified.

Numerical inconsistencies

2 findings · worst critical

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks. 2 reported summary statistics mathematically impossible for the stated N (PERCENT).

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior trials (COLCOT, LoDoCo2, CHANCE, CONVINCE) and notes both beneficial and null results, acknowledging the need for more data. The rationale for the trial is clearly stated: 'Given the biological rationale and encouraging evidence, we conducted the CLEAR trial to provide examine the effect of colchicine in post-myocardial infarction patients.' Limitations of prior work are implicitly addressed by designing a larger trial with more events, as discussed in the Discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials and biological rationale for colchicine, and logically links this to the study objective.

Evidence

“A trial of 4745 patients where colchicine was initiated within 30 days of a myocardial infarction and a trial of 5522 patients with stable coronary artery disease reported beneficial cardiovascular effects of colchicine, whereas 2 recent trials in patients with ischemic stroke (n=8343, n=3154) reported no reductions in cardiovascular events with colchicine with the caveat that one trial was a short term treatment trial (3 months).”

Introduction ¶1Find in source

“Given the biological rationale and encouraging evidence, we conducted the CLEAR trial to provide examine the effect of colchicine in post-myocardial infarction patients.”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on inflammation and colchicine, and provides a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

“Given the biological rationale and encouraging evidence, we conducted the CLEAR trial to provide examine the effect of colchicine in post-myocardial infarction patients.”

Introduction ¶1Find in source

Randomization used permuted blocks within a 24-hour computerized central system, stratified by center and STEMI/NSTEMI. Blinding was comprehensive: 'All participants, investigators, healthcare providers, data collectors and outcome adjudicators were blinded to treatment allocation.' The sample size was calculated and later increased based on blinded interim event rates. Inclusion/exclusion criteria were pre-specified and modified with a protocol amendment. The analysis population (intention-to-treat) and on-treatment sensitivity analyses are defined. Outlier handling is not explicitly discussed, but missing data are addressed as likely missing at random.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified analysis populations.

Evidence

“Randomization was performed using permuted blocks within a 24-hour computerized central system at the Population Health Research Institute.”

MethodsFind in source

“All participants, investigators, healthcare providers, data collectors and outcome adjudicators were blinded to treatment allocation.”

MethodsFind in source

“The initial sample size calculation for cardiovascular death, recurrent myocardial infarction or stroke was based on a time-to-event analysis with an anticipated control event rate of 15% at three years, 80% power, a 2-sided type 1 error level of 5%, a 2% loss to follow-up in both arms, study drug discontinuation of 12.5%, and the assumption of no interaction with spironolactone.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size calculation, and pre-specified outcomes.

Evidence

“Randomization was performed using permuted blocks within a 24-hour computerized central system at the Population Health Research Institute. Randomization was stratified by study center and whether the patient had a STEMI or NSTEMI.”

MethodsFind in source

“All participants, investigators, healthcare providers, data collectors and outcome adjudicators were blinded to treatment allocation.”

MethodsFind in source

The paper reports sex (20.4% female overall), age (mean 61 years), and detailed baseline characteristics including comorbidities, medications, and procedural details. Demographics include race/ethnicity and geographic region. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and comorbidities.

Evidence

“Baseline characteristics were well balanced between the groups, with the overall mean age being 61 years and 20.4% of patients being female (Table 1).”

Results ¶1Find in source

“Race or ethnic group (%) American Indian or Alaskan Native 7 (0.2) 3 (0.1) Asian 95 (2.7) 89 (2.5) Black or African American 24 (0.7) 23 (0.7) Native Hawaiian or Other Pacific Islander 9 (0.3) 9 (0.3) White 3233 (91.6) 3249 (91.9) Other 153 (4.3) 159 (4.5)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and comorbidities.

Evidence

“Age, years (mean ±SD) 60.6 ±10.3 60.7 ±10.3”

Table 1Find in source

“Diabetes Mellitus (%) 658 (18.7) 645 (18.3)”

Table 1Find in source

The paper states: 'Ethics committees of participating centers and national regulatory authorities approved the trial. All patients provided written informed consent.' This satisfies both IRB approval and informed consent. Regulatory compliance is implied by the approval of national regulatory authorities, though not explicitly naming a framework like the Declaration of Helsinki, but the statement is adequate.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“Ethics committees of participating centers and national regulatory authorities approved the trial. All patients provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“Ethics committees of participating centers and national regulatory authorities approved the trial. All patients provided written informed consent.”

MethodsFind in source

The study drug is identified: 'Study drugs were colchicine tablets of 0.5 mg and spironolactone tablets of 25 mg or matching placebos. Tiofarma, Netherlands, provided both study drugs with raw materials produced by Indena S.p.A., Milan, Italy.' This provides manufacturer and formulation. Statistical software is not explicitly named, but the analysis methods are described. Other bench resources are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (colchicine) is adequately identified, and statistical software is identified.

Evidence

“Study drugs were colchicine tablets of 0.5 mg and spironolactone tablets of 25 mg or matching placebos. Tiofarma, Netherlands, provided both study drugs with raw materials produced by Indena S.p.A., Milan, Italy.”

MethodsFind in source

PASSReviewer 2· 90% conf

The investigational product (colchicine) and placebo are identified with manufacturer and dosing details.

Evidence

MethodsFind in source

The primary analysis used a log-rank test and Cox proportional hazards model, with Fine-Gray for competing risks. Exact p-values are reported (e.g., p=0.93 for primary outcome). Effect sizes are reported with 95% CIs. Statistical software is not explicitly named, but the methods are described in detail. Data presentation includes Kaplan-Meier curves and tables with per-group n. Mathematical plausibility checks were not performed due to large N and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

“A two-sided, log-rank test was used to compare the two randomized groups. A p-value of less than 0.05 was considered significant. The hazard ratio and 95% confidence interval were estimated using a Cox proportional hazards regression model with the treatment group as the independent variable stratifying by spironolactone or placebo and STEMI or NSTEMI.”

MethodsFind in source

“The primary outcome occurred in 322 of 3528 patients (9.1%) in the colchicine group compared with 327 of 3524 patients (9.3%) in the placebo group (hazard ratio [HR], 0.99; 95% CI 0.85-1.16; P=0.93)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

MethodsFind in source

ResultsFind in source

The paper does not include an explicit data availability statement in the provided text. The trial is registered (NCT03048825), but no repository or access mechanism is mentioned. Since this is a clinical trial with patient data, managed access would be acceptable, but the absence of any statement is a gap. Code sharing is not applicable as no custom code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no code is shared.

Evidence

absence[Entire paper]

No data availability statement is found.

WARNReviewer 2· 80% conf

A data availability statement is present but vague, and no data repository or code sharing is mentioned.

Evidence

absence[Entire paper]

No data availability statement is found in the paper.

The trial is registered (NCT03048825). Methods are detailed enough for replication. Limitations are explicitly discussed in a dedicated section. Conclusions are proportional to the results, acknowledging the null finding. Funding sources and conflicts are stated. A reporting guideline (CONSORT) is not explicitly mentioned, but the paper follows standard reporting.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“Trial registration: ClinicalTrials.gov number NCT03048825”

AbstractFind in source

“First, based on the 95% CI of the primary outcome results, we cannot exclude a benefit of 15% or smaller, that could be clinically important.”

LimitationsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“Trial registration: ClinicalTrials.gov number NCT03048825”

AbstractFind in source

“First, based on the 95% CI of the primary outcome results, we cannot exclude a benefit of 15% or smaller, that could be clinically important.”

LimitationsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 12 references by DOI: 12 verified.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly typo, grammar, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally trustworthy, but readers should weigh the missing data availability statement and the minor internal inconsistency in the primary outcome denominator (3524 vs 3534). These do not undermine the main conclusions but warrant attention; an erratum or clarification may be appropriate for the denominator issue.

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 2.7% does not match the reported count 137/3528
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 2.8% does not match the reported count 139/3534
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
Add a data availability statement in the Methods or a dedicated section, specifying how de-identified patient data can be accessed (e.g., via a data access committee or a repository like YODA/Vivli) with conditions and timeframe.
The paper currently lacks any data availability statement, which is a reporting gap for a data-driven clinical trial.
4.
HIGHstatistics
Reconcile the denominator for the placebo group in the primary outcome sentence (Results, Efficacy) with Table 2 (3524 vs 3534) and correct the inconsistency.
An internal contradiction in a key result undermines trust and could warrant an erratum.
5.
MEDIUMreporting
Explicitly name the statistical software used (e.g., SAS version 9.4, R version 4.2) in the Statistical Considerations section.
Identifying software is part of methodological transparency and aids reproducibility.
6.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a footnote, and include the completed checklist as supplementary material.
Explicitly stating CONSORT adherence is standard for clinical trials and improves transparency.
7.
MEDIUMcopyedit
Fix the typo in the Introduction and Abstract: remove 'provide' from 'to provide examine the effect'.
Typographical errors detract from professionalism.
8.
MEDIUMcopyedit
Fix the missing parenthesis in Methods, Statistical Considerations: 'Prentice, William, Peterson (PWP) model' and clarify the sentence structure.
Grammar and clarity issues in the methods section can confuse readers.
9.
LOWrigor
Clarify the handling of outliers in the statistical analysis, even if only to state that no outliers were excluded or that sensitivity analyses were performed.
Outlier handling is a minor reporting gap that reviewers may ask about.
10.
LOWrigor
Provide a more detailed description of the randomization implementation, including the specific software or system used for the 24-hour computerized central system.
Additional detail on randomization sequence generation would enhance reproducibility.
11.
LOWreporting
Consider including a statement about the availability of the trial protocol and statistical analysis plan, perhaps as supplementary files or a link.
Sharing the protocol and SAP is good practice and supports transparency.
12.
LOWreporting
Include a CONSORT flow diagram in the main text or supplementary, as it is standard for clinical trials.
A flow diagram improves clarity on patient disposition.

Full text (29,601 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Colchicine in Acute Myocardial Infarction.

Read full text

DOI

10.1056/NEJMoa2405922

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/9db5c8f6-a3d3-473b-abb3-e930f58dc949" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/9db5c8f6-a3d3-473b-abb3-e930f58dc949/badge" alt="Kaimen Rigor review — 1★ (Critical), 2 critical, 2 high issues for “Colchicine in Acute Myocardial Infarction.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

5cdb643392898a59f05e73f869491949e38e1491a294a98b1b354283f8e5e78a

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×2−2★
IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 6 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues2 demonstrable

01Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
2.7% does not match the reported count 137/3528
“Coronary artery bypass grafting (%) 137 (2.7)”
Table 1Find in source
02Printed percentage does not match its own countdemonstrable
criticalArithmeticrecomputedFull detail
2.8% does not match the reported count 139/3534
“Coronary artery bypass grafting (%) 139 (2.8)”
Table 1Find in source

Findings by category

201ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit7 minor suggestions

Numerical inconsistencies

2 findings · worst critical

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions

1 finding · worst low

Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior trials and biological rationale for colchicine, and logically links this to the study objective.

Evidence

Introduction ¶1Find in source

“Given the biological rationale and encouraging evidence, we conducted the CLEAR trial to provide examine the effect of colchicine in post-myocardial infarction patients.”

IntroductionFind in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on inflammation and colchicine, and provides a logical rationale for the trial.

Evidence

Introduction ¶1Find in source

“Given the biological rationale and encouraging evidence, we conducted the CLEAR trial to provide examine the effect of colchicine in post-myocardial infarction patients.”

Introduction ¶1Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingINADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, sample size calculation, and pre-specified analysis populations.

Evidence

“Randomization was performed using permuted blocks within a 24-hour computerized central system at the Population Health Research Institute.”

MethodsFind in source

“All participants, investigators, healthcare providers, data collectors and outcome adjudicators were blinded to treatment allocation.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding, sample size calculation, and pre-specified outcomes.

Evidence

MethodsFind in source

“All participants, investigators, healthcare providers, data collectors and outcome adjudicators were blinded to treatment allocation.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and comorbidities.

Evidence

“Baseline characteristics were well balanced between the groups, with the overall mean age being 61 years and 20.4% of patients being female (Table 1).”

Results ¶1Find in source

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, race, and comorbidities.

Evidence

“Age, years (mean ±SD) 60.6 ±10.3 60.7 ±10.3”

Table 1Find in source

“Diabetes Mellitus (%) 658 (18.7) 645 (18.3)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“Ethics committees of participating centers and national regulatory authorities approved the trial. All patients provided written informed consent.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

“Ethics committees of participating centers and national regulatory authorities approved the trial. All patients provided written informed consent.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (colchicine) is adequately identified, and statistical software is identified.

Evidence

MethodsFind in source

PASSReviewer 2· 90% conf

The investigational product (colchicine) and placebo are identified with manufacturer and dosing details.

Evidence

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals.

Evidence

MethodsFind in source

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

MethodsFind in source

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no code is shared.

Evidence

absence[Entire paper]

No data availability statement is found.

WARNReviewer 2· 80% conf

A data availability statement is present but vague, and no data repository or code sharing is mentioned.

Evidence

absence[Entire paper]

No data availability statement is found in the paper.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“Trial registration: ClinicalTrials.gov number NCT03048825”

AbstractFind in source

“First, based on the 95% CI of the primary outcome results, we cannot exclude a benefit of 15% or smaller, that could be clinically important.”

LimitationsFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“Trial registration: ClinicalTrials.gov number NCT03048825”

AbstractFind in source

“First, based on the 95% CI of the primary outcome results, we cannot exclude a benefit of 15% or smaller, that could be clinically important.”

LimitationsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 12 references by DOI: 12 verified.

Copyediting

7 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 7 minor suggestions below.

7 copyedit issues flagged: mostly typo, grammar, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 2.7% does not match the reported count 137/3528
Demonstrable critical failure — blocks the verdict from passing.
2.
CRITICALstatistics
Correct or explain the statistically impossible value: PERCENT: 2.8% does not match the reported count 139/3534
Demonstrable critical failure — blocks the verdict from passing.
3.
HIGHdata code
Add a data availability statement in the Methods or a dedicated section, specifying how de-identified patient data can be accessed (e.g., via a data access committee or a repository like YODA/Vivli) with conditions and timeframe.
The paper currently lacks any data availability statement, which is a reporting gap for a data-driven clinical trial.
4.
HIGHstatistics
Reconcile the denominator for the placebo group in the primary outcome sentence (Results, Efficacy) with Table 2 (3524 vs 3534) and correct the inconsistency.
An internal contradiction in a key result undermines trust and could warrant an erratum.
5.
MEDIUMreporting
Explicitly name the statistical software used (e.g., SAS version 9.4, R version 4.2) in the Statistical Considerations section.
Identifying software is part of methodological transparency and aids reproducibility.
6.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a footnote, and include the completed checklist as supplementary material.
Explicitly stating CONSORT adherence is standard for clinical trials and improves transparency.
7.
MEDIUMcopyedit
Fix the typo in the Introduction and Abstract: remove 'provide' from 'to provide examine the effect'.
Typographical errors detract from professionalism.
8.
MEDIUMcopyedit
Fix the missing parenthesis in Methods, Statistical Considerations: 'Prentice, William, Peterson (PWP) model' and clarify the sentence structure.
Grammar and clarity issues in the methods section can confuse readers.
9.
LOWrigor
Clarify the handling of outliers in the statistical analysis, even if only to state that no outliers were excluded or that sensitivity analyses were performed.
Outlier handling is a minor reporting gap that reviewers may ask about.
10.
LOWrigor
Provide a more detailed description of the randomization implementation, including the specific software or system used for the 24-hour computerized central system.
Additional detail on randomization sequence generation would enhance reproducibility.
11.
LOWreporting
Consider including a statement about the availability of the trial protocol and statistical analysis plan, perhaps as supplementary files or a link.
Sharing the protocol and SAP is good practice and supports transparency.
12.
LOWreporting
Include a CONSORT flow diagram in the main text or supplementary, as it is standard for clinical trials.
A flow diagram improves clarity on patient disposition.

Full text (29,601 chars)Analyzed: Aug 16, 2026